Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin

A technology for liver fibrosis and brown fat, applied in the field of prevention and/or treatment of non-alcoholic steatohepatitis, can solve problems such as non-existence, achieve inhibition of fibrosis, prevention or improvement of metabolic syndrome, and enhancement of prevention and/or treatment or the effect of the therapeutic effect

Pending Publication Date: 2022-02-01
思尼特生物科技有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there are no reports on the effects of taxifolin on suppressing liver fibrosis and activation of brown adipocytes, and there are no reports on the use of taxifolin as a preventive and / or therapeutic agent for NASH accompanied by fibrosis example does not exist

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin
  • Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin
  • Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0138] Hereinafter, the present invention will be described in more detail based on test examples and formulation examples, but the present invention is not limited by the test examples and formulation examples, and can be varied within the range not departing from the scope of the present invention. In addition, reagents, devices, materials, etc. used in the present invention are commercially available unless otherwise mentioned.

[0139] Taxifolin used in the following test examples was purchased from Ametis JSC (Russia) as it was.

preparation example 1

[0242] Formulation example 1 (manufacture of tablet)

[0243] 1) Taxifolin 50g

[0244] 2) Lactose 50g

[0245] 3) Corn starch 15g

[0246] 4) Carboxymethylcellulose calcium 44g

[0247] 5) Magnesium stearate 1g

[0248] 1000 pieces total 160g

[0249] The total amount of 1), 2), 3) and 30 g of 4) were kneaded with water, dried in vacuum, and then sized. After the granulation, 14 g of 4) and 1 g of 5) were mixed, and compressed by a tablet machine. In this way, 1000 tablets each containing 50 mg of taxifolin were obtained.

preparation example 2

[0250] Formulation Example 2 (Manufacture of Capsules)

[0251] 1) Taxifolin 50mg

[0252] 2) Micronized cellulose 10mg

[0253] 3) Lactose 19mg

[0254] 4) Magnesium stearate 1mg

[0255] Total 80mg

[0256] 1), 2), 3) and 4) are mixed and filled into gelatin capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide: a novel hepatic fibrosis-inhibiting agent or brown fat cell-activating agent; and a drug for preventing and / or treating non-alcoholic fatty hepatitis and containing said agent as an active ingredient. The present invention pertains to: a hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin as an active ingredient; and a drug for preventing and / or treating non-alcoholic fatty hepatitis and containing taxifolin as an active ingredient.

Description

technical field [0001] The present invention relates to a hepatic fibrosis inhibitor and a brown fat cell activator containing taxifolin as an active ingredient. In addition, the present invention also relates to the use of a taxifolin-containing hepatic fibrosis inhibitor for the prevention and / or treatment of nonalcoholic steatohepatitis. Background technique [0002] Obesity has also increased in Japan due to the Westernization of diet and lack of exercise, and the number of people with diabetes and metabolic syndrome has risen to 22 million and 20 million, respectively, including pre-existing patients. In addition, with the increase of obese population in recent years, patients with nonalcoholic fatty liver disease (hereinafter referred to as "NAFLD") such as nonalcoholic steatohepatitis (hereinafter referred to as "NASH") It has increased sharply to about 30% of the physical examination, estimated to be close to 15-23 million people, and according to the latest data, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61K36/15A61P1/16A61P31/14A61P31/20A61P37/02A23L33/105
CPCA61K31/353A61K36/15A61P1/16A61P31/14A61P31/20A61P37/02A23L33/105A23V2002/00A23V2250/2116A23V2200/30A23V2200/308A61P43/00A61K31/352
Inventor 浅原哲子井上隆之田中将志猪原匡史齐藤聪
Owner 思尼特生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap